OUS Data: What does the CE Mark Really Mean?

Slides:



Advertisements
Similar presentations
Tips to a Successful Monitoring Visit
Advertisements

© Safeguarding public health Implementing Medical Device Regulation and Maintaining Patient Safety Name Nicola Lennard Date October 2011.
GCP compliance for GenISIS  This presentation is intended for clinical staff involved in recruiting patients to the GenISIS (Genetics of Influenza Susceptibility.
Pharmacists Responsibilities in Clinical Studies Mike R Sather, PhD Crystal L Harris, PharmD February 26, 2004.
Entering the North American Market
GLOBAL REGULATORY STRATEGY CONSIDERATIONS SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES SEPTEMBER 14-17, 2008 BOSTON, MA.
Good Clinical Practice GCP
Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.
Regulatory Authority Governing Clinical Trials Anthony J. Minisi, MD Director, Cardiology Fellowship Program.
Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.
FDA Focus On Consumer Protection
How to Register A Foreign Medical Device. SFDA Approval Documents Preparation Translation Create a Chinese Registration Standard Safety Testing in an.
MassMedic Presentation Innovation Accelerated SM.
UC c EN. Through Medtronic sponsored research, the Transcatheter Aortic Valves clinical portfolio is studying over 11,000 subjects at over 125.
Using Australian Clinical Sites – Challenges for International Sponsors Prof A J (Tony) Webber Clinical Network Services Pty Ltd Brisbane, Australia.
WORKSHOP ON ACCREDITATION OF BODIES CERTIFYING MEDICAL DEVICES INT MARKET TOPIC 9 CH 8 ISO MEASUREMENT, ANALYSIS AND IMPROVEMENT INTERNAL AUDITS.
CLAUDIA PANAIT TAIEX Expert – European Commission Legal Adviser Ministry of Health, ROMANIA.
THE OFFICE FOR REGISTRATION OF MEDICINAL PRODUCTS, MEDICAL DEVICES AND BIOCIDAL PRODUCTS Responsibility in the handling of medical devices.
GCP (GOOD CLINICAL PRACTISE)
Workshop on conformity assessment procedures and certification of medical devices INT MARKT Kyiv, November 2011 Conformity assessment of medical.
Responsibilities of Sponsor, Investigator and Monitor
November 9, 2015 February 20, 2017 Using real world evidence – industry perspective Pma indication expansion Melissa hasenbank, phd Sr. Clinical Research.
Medical Device Software Development
Contingent Workforce: Cerner Quality System & Regulations
CLI and Device Intervention Across the Pacific – An FDA View
Rachel Neubrander, PhD Division of Cardiovascular Devices
What should be the optimal Design for TAVI Procedure.
GOOD MANUFACTURING PRACTICE FOR BIOPROCESS ENGINEERING (ERT 425)
Recent Evolution of New Drug Review and Approval System in Korea
Responsibilities of Sponsor, Investigator and Monitor
Regulatory Basics: Europe and the CE Mark
Are we ready to perform TAVI in Intermediate Risk Patients?
Investigator-initiated Research What Are your Responsibilities?
Jeff Shuren, MD, JD Center for Devices and Radiological Health U. S
The Information Professional’s Role in Product Safety
ICH-GCP Avinash Kondawar M. Pharm Lead CRA
FDA’s IDE Decisions and Communications
How to Put Together an IDE Application
Balancing Regulation and Innovation: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
How to Apply for and Receive Industry Funding for Investigator Sponsored Research Chuck Simonton MD, FACC, FSCAI Chief Medical Officer Abbott Vascular.
Administering Informed Consent Issues for Discussion
MITRALIGN: Direct Annuloplasty
Reasonable Assurance of Safety and Effectiveness: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division.
Japan-USA Synergies: Academic View
The Current PMA Requirements
REGULATORY PROBLEMS IN CARING OUT PRE- AND POST- AUTHORISATION CLINICAL TRIALS Dr Penka Decheva GCP Inspector, BDA.
First-in-Man, First In The USA: What’s The Difference?
What Kind of Aspects can Physicians Look Forward To? US Physician View
Medtronic - Core Valve Eberhard Grube, MD, FACC, FSCAI
CRT 2010 Washington DC, January 21, 2010
Progress with the Sadra Medical Lotus™ Valve System
Deputy Director, Division of Biostatistics No Conflict of Interest
Lessons Learned Through HBD: The Industry’s View
Introduction of New Technology: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
CRT 2010 Washington DC, January 21, 2010
Benefits of US EFS: A Clinical Perspective
Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Early Feasibility in the USA –An Academic View
US Early Feasibility Studies (EFS)
Lessons Learned Through HBD: The Regulator’s View - US FDA
Bozeman Health Clinical Research
Erica Takai, PhD for Andrew Farb, M.D.
Roles and Responsibilities of the Clinical Research Team
1888 Press Release - Spine Care Technologies Inc. and mdi Consultants Inc. Announce Strategic Alliance
How and why this study may change my practice ?
Cardiovascular Device Development and Approval: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of.
INTERFACES BETWEEN NATIONAL LEGISLATION AND DIRECTIVE 97/23/EC
Seán Balfe Director, Sustainability and the Built Environment.
Regulation in South-East Asia Joint Drugs Controller (India)
Good clinical practice
Presentation transcript:

OUS Data: What does the CE Mark Really Mean? CRT 2010 Washington DC, January 21, 2010 OUS Data: What does the CE Mark Really Mean? Eberhard Grube, MD, FACC, FSCAI St.Elisabeth Hospital, Essen, Germany, Heart Center Rhein Ruhr Instituto Cardiologico Dante Pazzanese, São Paulo, Brazil

Eberhard Grube, MD DISCLOSURES Consulting Fees Honoraria Abbott Vascular, Boston Scientific Corporation, Cordis, a Johnson & Johnson Company, Medtronic CardioVascular, Inc. Honoraria Biosensors International , Boston Scientific Corporation, Medtronic CardioVascular, Inc Ownership Interest (Stocks, Stock Options or Other Ownership Interest) Biosensors International , Medtronic CardioVascular, Inc. I intend to reference unlabeled/ unapproved uses of drugs or devices in my presentation. I intend to reference off-label use of stents and valve prosthesis.

What does the CE Mark Mean? The CE Mark means a medical device is in compliance with Essential Requirements of European Directives 93/42/EEC and 90/385/EEC Compliance with these requirements ensures a high degree of: Health protection Performance Safety ……for patients and users. 3

What does the CE Mark Mean? In the EU, the CE Mark is focused more on Safety Reimbursement of the device in specific countries is focused more on effectiveness Therefore, patients have potential access to a device once it is deemed safe, but the government will not pay for it until it is deemed clinically effective and in many cases cost-effective as well. 4

CE Mark: Who are the Players? Manufacturer Notified Bodies Competent Authorities 5

CE Marking Responsibilities Manufacturer: Placing a product on the market Fulfilling relevant legal requirements Tracking the product on the market Notifying Competent Authorities in Member States when incidents occur 6

CE Marking Responsibilities Notified Bodies: Independent auditing of manufacturer Certification of the quality system at the manufacturer Certification of specific products There are notified bodies in all member states 7

CE Marking Responsibilities Competent Authorities: Ensure requirements of the Medical Device Directive are carried out in the Member State (country) Oversee the notified body Ensure adverse incidents are reported appropriately Manufacturers must register with the competent authority in their country and specify the devices they market 8

EU Class III Requirements For Class III: Medical devices in heart or central nervous system, Combo Products, etc. Clinical Investigation approved by Competent Authority of Member State Certification for Full Quality System of manufacturer by Notified Body (NB) Type test of medical device for Essential Requirements by NB Review Design Dossier, pre-market inspection by NB, then Approval of CE marking 9

Once a CE Mark is Received The company is free to market the device in the EU Certain countries outside of EU also recognize the CE Mark The CE Mark in and of itself does may not help with approval in the US/Japan, but a positive track record in the EU may have a positive influence, and a negative track record can hurt you Provides additional strategic options to support a US submission 10

The CE Mark Creates Strategic Options Begin to sell product in the EU to support development efforts and generate track record (may need reimbursement in key countries) CoreValve example Edwards example Use the CE Mark to start a pilot trial in the EU, to support an IDE submission for pivotal in the US EU clinical sites can be leveraged to support enrollment in a US pivotal trial 11

Strategic Options Begin to sell product in the EU to support the development efforts: - CoreValve example (had reimbursement) Built a Pan-European distributor network Built sales from 0 to ________ in ____ months Revenue line built value for the company Company was then able to support progress on the device Value was recognized by the market w/o USA piece 12

Strategic Options Begin to sell product in the EU to support development efforts: Edwards example (had reimbursement) Built a network of distributors and direct sales Built strong sales in Europe that built a positive clinical track record Sales and positive clinical track record helped support significant investment in US pivotal trial Company was also then able to support significant progress on device development 13

EU Clinical Data- for US Requirements: EU Clinical investigations to be performed in accordance with EN ISO 14155 Clinical Investigations of Medical Devices for Human Subject Clinical Investigations to be performed in accordance with ICH Good Clinical Practice (GCP) Guidelines ICH GCP compliant clinical investigations are also required by FDA under IDE Essentially, the clinical data requirements are the same in the US and EU 14

OUS Clinical Data- For U.S. KEY to Success: Obtain early clinical and regulatory feedback from FDA in a Pre-IDE meeting including: Bench testing, preclinical testing and clinical testing requirements for IDE European and U.S. Clinical Development Plan- FIM, Safety and Benefit, Safety and Efficacy (Pivotal) Clinical site list – have they supported a US trial before? Identification of threshold for cases performed outside the US…. 30% ? 40% ? 50%? 15

OUS Clinical Data- For U.S. KEY to Success: Obtain early clinical and regulatory feedback from FDA in a Pre-IDE meeting including: Specific Clinical Protocols (OUS, US, Global) Clinical Trial Design: RCT versus Registry Endpoints: Safety and Efficacy Testing and Follow-up requirements Statistical plan Data/Safety Monitoring & CEC adjudication 16

What the Future Holds A New Medical Device Directive in the EU takes effect on March 21 A more unified approach among notified bodies CE Mark for certain devices could become more difficult More clinical trials will be required prior to CE Mark This will have to be taken into account when thinking of the CE Mark as leverage for US submissions 17

Summary The CE Mark provides assurance that a device complies with regulations, holds a certain level of quality and is SAFE. The CE Mark can allow the initiation of sales in the EU, that when coupled with reimbursement can support further development efforts The CE Mark can allow the initiation of trials in the EU to generate clinical data to support a US submission Clinical data collection standards are similar in the US and EU Any effort to use EU data for a US submission should be discussed with the FDA 18